These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 37545218)
1. Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers. Bogar F; Ak G; Metintas S; Ayhanci A; Metintas M Cancer Biomark; 2023; 38(1):111-120. PubMed ID: 37545218 [TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332 [TBL] [Abstract][Full Text] [Related]
3. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760 [TBL] [Abstract][Full Text] [Related]
4. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma. de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314 [TBL] [Abstract][Full Text] [Related]
5. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420 [TBL] [Abstract][Full Text] [Related]
6. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782 [TBL] [Abstract][Full Text] [Related]
8. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616 [TBL] [Abstract][Full Text] [Related]
9. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406 [TBL] [Abstract][Full Text] [Related]
10. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications. Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072 [TBL] [Abstract][Full Text] [Related]
12. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma. Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL Front Immunol; 2023; 14():1268927. PubMed ID: 37901248 [TBL] [Abstract][Full Text] [Related]
13. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [TBL] [Abstract][Full Text] [Related]
14. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982 [TBL] [Abstract][Full Text] [Related]
15. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775 [TBL] [Abstract][Full Text] [Related]
16. ATG5 as biomarker for early detection of malignant mesothelioma. Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279 [TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]